The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma
Abstract
This study was designed to determine if macrophage inhibitory protein-1 (MIP-1), a recently described osteoclast (OCL) stimulatory factor,1 was present in marrow from patients with multiple myeloma (MM) and possibly involved in the bone destructive process. MIP-1, but not interleukin-1β (IL-1β), tumor necrosis factor-β (TNF-β), or interleukin-6 (IL-6), messenger RNA was elevated in freshly isolated bone marrow from 3 of 4 patients with MM compared to normal controls. Furthermore, enzyme-linked immunosorbent assays of freshly isolated bone marrow plasma detected increased concentrations of hMIP-1 (range, 75-7784 pg/mL) in 8 of 13 patients (62%) with active myeloma, in 3 of 18 patients (17%) with stable myeloma (range, 75-190.3), as well as in conditioned media from 4 of 5 lymphoblastoid cell lines (LCLs) derived from patients with MM. Mildly elevated levels of MIP-1 were detected in 3 of 14 patients (21%) with other hematologic diagnoses (range, 80.2-118.3, median value of 96 pg/mL) but not in normal controls (0 of 7). MIP-1 was not detected in the peripheral blood of any patients with MM. In addition, recombinant hMIP-1 induced OCL formation in human bone marrow cultures. Importantly, addition of a neutralizing antibody to MIP-1 to human bone marrow cultures treated with freshly isolated marrow plasma from patients with MM blocked the increased OCL formation induced by these marrow samples but had no effect on control levels of OCL formation. Thus, high levels of MIP-1 are expressed in marrow samples from patients with MM, but not in marrow from patients with other hematologic disorders or controls, and support an important role for MIP-1 as one of the major factors responsible for the increased OCL stimulatory activity in patients with active MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y., & Roodman, G. D. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.11.4226 · Cited by 486
Self-citationBataille, R., Jourdan, M., Zhang, X. G., & Klein, B. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114392 · Cited by 479
Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity.
Olsson, L., & Kaplan, H. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5429 · Cited by 379
Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma Cells
Garrett, I. R., Durie, B. G. M., Nedwin, G. E., Gillespie, A., Bringman, T., Sabatini, M., Bertolini, D. R., & Mundy, G. R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708273170902 · Cited by 373
Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.
Roodman, G. D., Kurihara, N., Ohsaki, Y., Kukita, A., Hosking, D., Demulder, A., Smith, J. F., & Singer, F. R. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115584 · Cited by 366
Self-citationMatsuoka, Y., Moore, G. E., Yagi, Y., & Pressman, D. (1967) · Experimental Biology and Medicine · doi:10.3181/00379727-125-32327 · Cited by 287
Horton, M. A., Lewis, D., McNulty, K., Pringle, J. A. S., & Chambers, T. J. (1985) · PubMed · Cited by 275
Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P., & Alexandre, C. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1909 · Cited by 241
The role of MIP-1α in Inflammation and hematopoiesis
Cook, D. N. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.59.1.61 · Cited by 214
Production of interleukin-1 by bone marrow myeloma cells
Cozzolino, F., Torcia, M., Aldinucci, D., Rubartelli, A., Miliani, A., Shaw, A., Lansdorp, P., & Di Guglielmo, R. (1989) · Blood · doi:10.1182/blood.v74.1.380.380 · Cited by 185
Production of cytokines by bone marrow cells obtained from patients with multiple myeloma
Lichtenstein, A. K., Berenson, J., Norman, D., Chang, M., & Carlile, A. (1989) · Blood · doi:10.1182/blood.v74.4.1266.1266 · Cited by 149
Cytokine Network in Human Multiple Myeloma
Klein, B., & Bataille, R. (1992) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30344-7 · Cited by 145
Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma
Kawano, M., Tanaka, H., Ishikawa, H., Nobuyoshi, M., Iwato, K., Asaoku, H., Tanabe, O., & Kuramoto, A. (1989) · Blood · doi:10.1182/blood.v73.8.2145.2145 · Cited by 131
Devlin, R. D., Reddy, S. V., Savino, R., Ciliberto, G., & Roodman, G. D. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.3.393 · Cited by 126
Self-citationFuller, K., Owens, J., & Chambers, T. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.11.6065 · Cited by 112
Fahey, J. L., Buell, D. N., & Soxt, H. C. (1971) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1971.tb13537.x · Cited by 104
Development of an in vivo model of human multiple myeloma bone disease
Alsina, M., Boyce, B. F., Devlin, R. D., Anderson, J. L., Craig, F. E., Mundy, G. R., & Roodman, G. D. (1996) · Blood · doi:10.1182/blood.v87.4.1495.bloodjournal8741495 · Cited by 97
Self-citationEstablishment of a human plasma cell line in vitro.
Burk, K. H., Drewinko, B., Turjillo, J. M., & Ahearn, M. J. (1978) · PubMed · Cited by 97
Bone destruction and hypercalcemia in plasma cell myeloma.
Mundy, G. R., & Bertolini, D. R. (1986) · PubMed · Cited by 88
Kukita, T., Nomiyama, H., Ohmoto, Y., Kukita, A., Shuto, T., Hotokebuchi, T., Sugioka, Y., Miura, R., & Iijima, T. (1997) · PubMed · Cited by 88
The incidence and epidemiology of plasma cell neoplasms.
Bergsagel, D. E. (1995) · PubMed · Cited by 60
PATHOGENESIS AND MANAGEMENT OF BONE LESIONS IN MULTIPLE MYELOMA
Bataille, R., Manolagas, S. C., & Berenson, J. R. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70435-4 · Cited by 59
Kukita, T., McManus, L. M., Miller, M., Civin, C. I., & Roodman, G. D. (1989) · PubMed · Cited by 53
Self-citationRitts, R. E., Ruı́z-Argüelles, A., Weyl, K. G., Bradley, A. L., Weihmeir, B., Jacobsen, D. J., & Strehlo, B. L. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310202 · Cited by 50
Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells
Tsujimoto, T., Lisukov, I., Huang, N., Mahmoud, M., & Kawano, M. (1996) · Blood · doi:10.1182/blood.v87.8.3375.bloodjournal8783375 · Cited by 41
Blood stem cell transplantation: From preclinical to clinical models
Fliedner, T. M. (1995) · Stem Cells · doi:10.1002/stem.5530130702 · Cited by 35
Chronic lymphoid leukemias: Recent advances in biology and therapy
Foon, K. A. (1995) · Stem Cells · doi:10.1002/stem.5530130103 · Cited by 18
Cited by
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Self-citationPlatelets, inflammation and tissue regeneration
Nurden, A. (2011) · Thrombosis and Haemostasis · doi:10.1160/ths10-11-0720 · Cited by 791
Macrophage inflammatory protein-1
Menten, P., Wuyts, A., & Van Damme, J. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00045-x · Cited by 706
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2465 · Cited by 593
Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R., & Costa, L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00216-3 · Cited by 570
Metadata
- Authors
- Choi, S. J., Cruz, J. C., Craig, F., Chung, H., Devlin, R. D., Roodman, G. D., & Alsina, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-07-15
- Volume
- 96
- Issue
- 2
- Pages
- 671-675
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W30364595
- Cited by
- 408
- References
- 27
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.